Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PRME | Prime Medicine, Inc. | 2026-10-08 08:46:05 | 3.77 | -0.12 | -3.21 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRME | 0001894562 | Prime Medicine, Inc. | US74168J1016 | — | — | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 60 FIRST ST. | CAMBRIDGE | MA | 02141 | UNITED STATES | US | 617-465-0013 | 60 FIRST ST., CAMBRIDGE, MA, 02141 | 60 FIRST ST., CAMBRIDGE, MA, 02141 | — | Biotechnology | 2019 | Allan Reine | — | http://primemedicine.com | 238,759,057 | 180,737,548 | 181,376,856 | Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts. | 2026-10-01 20:51:31 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 238,759,057 | -57,973,251 | -19.5372 | 180,552,179 | 49,391,337 | 37.6571 |
| 2024 | 296,732,308 | -306,395,344 | -50.8011 | 131,160,842 | 11,221,595 | 9.3561 |
| 2023 | 603,127,652 | 603,127,652 | 100 | 119,939,247 | 22,693,420 | 23.3361 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Ann Lee, Ph.D. | Chief Technical Officer | 2025 | 505,375 | 0 | — | 243,960 | 10,706 | 1,550,116 |
| Jeremy Duffield, M.D. | Chief Scientific Officer | 2025 | 268,271 | 0 | — | 0 | 380,926 | 1,317,797 |
| Allan Reine | Chief Executive Officer | 2025 | 606,212 | 0 | — | 402,000 | 57,177 | 3,894,187 |
| Keith Gottesdiener, M.D. | Chief Executive Officer | 2025 | 259,568 | 0 | — | 0 | 762,400 | 2,207,770 |
| Keith Gottesdiener | Chief Executive Officer, President | 2024 | 652,792 | 0 | — | 395,010 | 32,785 | 2,245,617 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 146 |
| 2024 | 214 |
| 2023 | 234 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 4,632,000 | 2,983,000 | — |
| Cost Of Revenue | — | — | — |
| Gross Profit | 4,632,000 | 2,983,000 | 0 |
| Research And Development Expenses | 160,636,000 | 155,289,000 | 147,905,000 |
| General And Administrative Expenses | 52,346,000 | 50,161,000 | 43,387,000 |
| Operating Expenses | 212,982,000 | 205,450,000 | 204,792,000 |
| Operating Income | -208,350,000 | -202,467,000 | -204,792,000 |
| Net Income | -201,142,000 | -195,882,000 | -198,133,000 |
| Earnings Per Share Basic | -1.35 | -1.65 | -2.18 |
| Earnings Per Share Diluted | -1.35 | -1.65 | -2.18 |
| Weighted Average Shares Outstanding Basic | 148,758,527 | 118,600,381 | 90,969,327 |
| Weighted Average Shares Outstanding Diluted | 148,758,527 | 118,600,381 | 90,969,327 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 63,032,000 | 182,476,000 | 41,574,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 674,000 | 14,667,000 | 2,254,000 |
| Total Assets Current | 181,293,000 | 211,886,000 | 142,976,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 20,572,000 | 24,404,000 | 22,659,000 |
| Other Assets Non Current | 1,000,000 | 0 | 779,000 |
| Total Assets Non Current | 161,440,000 | 85,622,000 | 50,875,000 |
| Total Assets | 342,733,000 | 297,508,000 | 193,851,000 |
| Accounts Payable | 8,887,000 | 11,351,000 | 19,537,000 |
| Deferred Revenue | 7,824,000 | 7,092,000 | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 12,600,000 | 15,904,000 | 14,110,000 |
| Total Liabilities Current | 37,448,000 | 37,961,000 | 56,423,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 184,417,000 | 106,398,000 | 4,357,000 |
| Total Liabilities | 221,865,000 | 144,359,000 | 60,780,000 |
| Common Stock | 2,000 | 2,000 | 2,000 |
| Retained Earnings | -888,354,000 | -687,212,000 | -491,330,000 |
| Accumulated Other Comprehensive Income | 82,000 | 1,000 | -15,000 |
| Total Shareholders Equity | 120,868,000 | 153,149,000 | 133,071,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 7,321,000 | 6,128,000 | 4,653,000 |
| Share Based Compensation Expense | 29,268,000 | 26,068,000 | 13,910,000 |
| Other Non Cash Income Expense | — | 0 | -28,000 |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -4,545,000 | 15,859,000 | 9,455,000 |
| Change In Accounts Payable | 996,000 | -5,257,000 | 9,140,000 |
| Change In Other Liabilities | -1,160,000 | 1,843,000 | 1,758,000 |
| Cash From Operating Activities | -162,564,000 | -122,865,000 | -165,412,000 |
| Purchases Of Marketable Securities | 205,413,000 | 129,449,000 | 104,951,000 |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 4,531,000 | 7,294,000 | 8,724,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -108,763,000 | 68,457,000 | 18,711,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 0 | 38,081,000 | 655,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 151,512,000 | 195,876,000 | 655,000 |
| Change In Cash | -119,815,000 | 141,468,000 | -146,046,000 |
| Cash At End Of Period | 63,032,000 | 182,476,000 | 41,574,000 |
| Income Taxes Paid | — | — | 0 |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.35 | -1.65 | -2.18 |
| Price To Earnings Ratio | -2.5704 | -1.7697 | -4.0642 |
| Earnings Growth Rate | -18.1818 | -24.3119 | -47.9714 |
| Price Earnings To Growth Ratio | 0.1414 | 0.0728 | 0.0847 |
| Book Value Per Share | 0.8125 | 1.2913 | 1.4628 |
| Price To Book Ratio | 4.2707 | 2.2613 | 6.0568 |
| Ebitda | -193,821,000 | -189,754,000 | -193,480,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 3,489,000 | 7,873,000 | 8,303,000 |
| Free Cash Flow | -166,053,000 | -130,738,000 | -173,715,000 |
| Return On Equity | -1.6641 | -1.279 | -1.4889 |
| One Year Beta | 1.9127 | 2.3995 | 1.7008 |
| Three Year Beta | 1.9601 | 1.8584 | 1.5601 |
| Five Year Beta | 1.8769 | 1.8584 | 1.5601 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Cahill Thomas | Director | 2026-06-05 | 75,000 | A | 75,000 |
| Chung Wendy | Director | 2026-06-05 | 75,000 | A | 75,000 |
| Foster-Cheek Kaye I | Director | 2026-06-05 | 75,000 | A | 75,000 |
| Kelly Michael Aaron | Director | 2026-06-05 | 75,000 | A | 75,000 |
| NELSEN ROBERT | Director, 10% owner | 2026-06-05 | 75,000 | A | 75,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| ENVESTNET ASSET MANAGEMENT INC | 2026-06-30 | 104,346 | 28,278 | 3.69 |
| STATE STREET CORP | 2026-06-30 | 27,957,137 | 7,576,460 | 3.69 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 2026-06-30 | 100,933 | 27,353 | 3.69 |
| Parkside Financial Bank & Trust | 2026-06-30 | 1,049 | 285 | 3.6807 |
| CITADEL ADVISORS LLC | 2026-06-30 | 511,803 | 138,700 | 3.69 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Pacer Funds Trust | 2026-07-31 | Pacer WealthShield ETF | PWS | 2,426 | 7,083.92 | 0.0294 |
| ETFis Series Trust I | 2026-07-31 | Virtus Biotech Clinical Trials ETF | BBC | 112,004 | 327,051.68 | 0.705 |
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Extended Market Index Fund | USMIX | 10,979 | 32,058.68 | 0.004 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 78,586 | 229,471.12 | 0.0083 |
| Global X Funds | 2026-07-31 | Global X Russell 2000 ETF | RSSL | 44,950 | 131,254 | 0.0088 |